A Single-Dose, 1-Period, 1-Treatment Pilot Study of an Investigational Capsule Formulation of 2 mg/.05 mg Buprenorphine/Naloxone Under Fasting Conditions.
Phase of Trial: Phase I
Latest Information Update: 02 Oct 2017
At a glance
- Drugs Buprenorphine/naloxone (Primary)
- Indications Opioid abuse
- Focus Pharmacokinetics
- Sponsors Nanotherapeutics; Ology Bioservices
- 02 Oct 2017 According to a Ology Bioservices media release, Nanotherapeutics changed its name to Ology Bioservices.
- 07 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Apr 2009 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov.